Vasculitis & polymyalgia rheumatica

Clinical manifestations, treatment and prognosis analysis of childhood antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis

Clin Exp RheumatolPublished Retrospective cohort study

Authors' conclusion

In this cohort, childhood-onset AAV occurred predominantly in females, with MPA as the major subtype and the kidneys being the most frequently involved organ. Glucocorticoids formed the mainstay of treatment. Approximately half of the children achieved remission following treatment. Patients with elevated serum creatinine levels are at higher risk of progressing to ESRD. Most children achieved long-term survival.

Study context

Population
Patients aged <18 years diagnosed with AAV at the First Affiliated Hospital of Zhengzhou University22 female
Participants
29 patients
Exposure
Microscopic polyangiitis (MPA) vs granulomatosis with polyangiitis (GPA)
  • MPAn = 23
Outcome
Progression to ESRD (risk factors)
Methodological detailssingle-centre
  • Single-centre

Main finding

As reported in the abstract

Progression to ESRD

Patients progressed to end-stage renal disease (ESRD)

15

ESRD at initial diagnosis

12

Observational data: associations, not effects.

Further findings

Diagnosis

Median age at diagnosis (IQR 12.3-16.5 years)
13.9 years
Median diagnostic interval (IQR 0.6-1.5 months)
1 month

Clinical manifestations

Most common: renal, respiratory and musculoskeletal involvement; presentations similar between MPA and GPA

Outcomes after treatment · 12 months post-treatment

Remission
12
Renal remission
3
Remained on dialysis
8
Renal transplantation
6
  • GC the mainstay of treatment

Long-term survival

Deaths
1
  • Long-term survival achieved in most patients

Original publication

Clinical manifestations, treatment and prognosis analysis of childhood ANCA-associated vasculitis. Clin Exp Rheumatol. Published 2 January 2026. doi:10.55563/clinexprheumatol/1aja3e

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.